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Abstract
Although IL-17 is a pro-inflammatory cytokine reportedly involved in various autoimmune inflammatory disorders, its role
remains unclear in murine models of colitis. Acute colitis was induced by 2.5% dextran sodium sulfate (DSS) treatment for 5
days. A novel sphingosine-1-phosphate receptor agonist W-061, a prototype of ONO-4641, was orally administered daily,
and histopathological analysis was performed on the colon. The number of lymphocytes and their cytokine production
were also evaluated in spleen, mesenteric lymph node, Peyer’s patch and lamina propria of the colon. Daily administration
of W-061 resulted in improvement of DSS-induced colitis, and significantly reduced the number of CD4+ T cells in the
colonic lamina propria. Numbers of both Th17 and Th1 cells were reduced by W-061 treatment. W-061, however, had no
influence on the number of Treg cells in lamina propria. Thus, Th17 and Th1 cells in lamina propria were thought to be the
key subsets in the pathogenesis of DSS-induced colitis. In conclusion, W-061 may be a novel therapeutic strategy to
ameliorate acute aggravation of inflammatory bowel diseases.
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Introduction
Inflammatory bowel diseases (IBDs), such as Crohn’s disease
(CD) and ulcerative colitis (UC), are chronic relapsing disorders of
the gastrointestinal tract [1]. In humans, CD is generally
characterized by elevated production of helper T (Th) 1 cytokines,
such as interferon (IFN)-c [2], while UC is characterized by the
enhanced expression of Th2 cytokines, such as interleukin (IL)-4
and IL-13 [3]. Recent clinical data have indicated that treatment
with infliximab, a chimeric anti-tumor necrosis factor (TNF)-a
antibody, was further effective as compared to azathioprine
therapy in patients with CD [4]. Despite its efficacy, infliximab
therapy for patients with rheumatoid arthritis (RA) was associated
with the risk of malignancies and serious infections, such as
tuberculosis [5]. Therefore, novel therapeutic strategies with
different mechanisms are required.
In recent years, Th17, a third subset of inflammatory helper T
cells that produce IL-17A, IL-17F, IL-22 and IL-23, was discovered
[6]. Th17 has been reported to be associated with aggravation of
various autoimmune inflammatory diseases, such as rheumatoid
arthritis and multiple sclerosis [7-9]. Although IL-17 expression in
the mucosa and its serum levels were increased in active IBD
patients [10], treatment strategies for the regulation of Th17
functions has not yet been established.
It has been reported that serum IL-17 concentration is elevated
in the acute phase in a dextran sodium sulfate (DSS)-induced
colitis model [11], however, the role of IL-17 remains unclear in
animal models of colitis. For example, controversial data have
been obtained in the DSS-induced colitis model [12,13] and CD4
+
CD45RB
high adoptive cell transfer model [14,15].
In contrast, regulatory T (Treg) cells are a distinct subset in
suppressing excessive immune responses [16]. This subset is
characterized by the presence of a surface marker, CD25, and a
transcription factor, Foxp3. In a CD4
+ CD45RB
high cell-transfer
colitis model, the development of colitis was suppressed by
concomitant transfer of CD4
+ CD25
+ T cells [17].
It was recently reported that sphingosine-1-phosphate (S1P)
receptor agonists, such as FTY720 (fingolimod), exhibited
immunodulatory function through induction of CD4
+ T cell
migration into secondary lymphoid tissues and sequestration of
these cells [18] and that FTY720, which has a particular binding
affinity for S1P1, was clinically effective in the treatment of
multiple sclerosis [19]. FTY720 was also reported to be effective
for the treatment of colitis in IL-10-deficient mice [20], DSS-
induced colitis and CD4
+CD62L
+ cell-transfer model [21].
Another S1P receptor agonist, KRP-203, was also useful for
colitis in IL-10 deficient mice [22]. However, the effects of these
agents on Th17 and Treg in colitis mice have not been examined
and reported to date.
W-061, a prototype of ONO-4641 [23], has recently been
developed to target S1P receptors. In the present study, we
evaluated the activity of W-061 on S1P receptors and the effects of
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23933this agent on specific T cells, such as Th17 and Treg, in a mouse
model of DSS-induced colitis.
Results
W-061 has specific agonistic activity on hS1P1
Compared to FTY720 phosphate, binding affinity of S1P
receptors and agonistic activity of W-061 was evaluated in CHO-
K1 cells. W-061 bound to human S1P receptors except for hS1P2
(Table 1). Its binding affinity of S1P receptors was lower than that
of FTY720 phosphate, however, W-061 had higher agonistic
activity on S1P1 compared to S1P3 (Table 2), while FTY720
phosphate had agonistic activity on S1P3 as well as S1P1.
Body weight and colon length were improved by
treatment of W-061
No change of body weight was observed in mice treated with
W-061 (3 mg/kg) alone (Figure S1). After 5-day DSS treatment,
body weight in each group was reduced by approximately 20%
(Figure 1A). After day 7, however, a significant body weight
increase was observed in W-061-treated mice (95.865.6% vs.
80.067.2% on day 10). DSS treatment induced a reduction in
colon length in each group; however, colon length in W-061
treated mice was significantly longer than in control mice on day
10 (10.860.6 cm vs. 9.161.6 cm, p,0.05).
Daily W-061 administration significantly promoted
recovery from acute DSS-induced colitis
Histological analysis indicated that cellular infiltration in the
lamina propria, mucin depletion and thickness of the mucosa were
severe in control mice when compared with W-061 treated mice
(Figure 1B). Mean histologic score in mice treated with W-061 was
significantly lower than in control mice (Figure 1C: 3.760.6 vs.
10.864.5).
Daily W-061 administration induced homing of
lymphocytes to secondary lymphoid tissues
The number of lymphocytes in LP was sequentially increased by
DSS treatment. However, W-061 administration suppressed
lymphocyte migration to SP and LP, and promoted their homing
to secondary lymphoid tissues, such as MLN and PP (Figure 2A–
D). Specifically, W-061 inhibited CD4
+ T cell migration to LP on
day 3, 6 and 10 (Figure 2D).
Daily W-061 administration inhibited migration of Th17
and Th1 to lamina propria
In the control group, an increase in the number of Th1 cells in
LP was observed following the increase in the number of Th17
cells. On the other hand, W-061 treatment inhibited the increase
in Th17 cells on days 6 and 10 (Figure 3D). In addition, W-061
also inhibited the increase in Th1 cells on day 10 (Figure 4D).
Instead, Th17 cells increased in PP on day 6, and Th1 cells
increased in MLN and PP on day 10. The number of Treg cells in
both groups increased on day 6 (Figure 5D); however, there was
no difference in the change in Treg cells. Changes in the number
of Th1, Th17 and Treg cells were also confirmed in SP, MLN and
PP (Figure 5A–C). In PP, the number of Th17 cells was
significantly higher in the W-061 group on day 6, and the
numbers of Th1 and Treg cells were significantly higher on day 10
(Figure 4C, 5C). Similarly, in MLN, the numbers of Th1 and Treg
cells were also significantly higher in W-061 group on day 10
(Figure 4B, 5B).
Discussion
In the clinical course of IBD, patients occasionally become
immunocompromised due to treatment with immunosuppressive
reagents, such as infliximab, steroids, antimetabolites and
calcineurin inhibitors. It has been reported that RA patients
receiving infliximab can develop serious opportunistic infections,
such as tuberculosis [5]. In terms of the potent properties in anti-
opportunistic infections [24] and anti-tumor effects [25,26], we
have been investigating the efficacy of S1P receptor agonists in
promoting lymphocyte homing and sequestrating lymphocytes
into secondary lymphoid organs. We previously reported the
usefulness of FTY720 and KRP-203 in IL-10-deficient mice as a
CD-like colitis model [20,22]. In this study, a novel and potent
S1P receptor agonist, W-061, which is structurally different from
sphingosine, was examined. In contrast to conventional S1P
receptor agonists, W-061, which is biologically active in vivo
without undergoing phosphorylation, is more specific to lympho-
cytes than FTY720.
We first evaluated the membrane binding activity of W-061 to
S1P receptors, which has five subtypes (S1P1-5) [18]. The specific
roles of S1P receptor subtypes have been reported, with S1P1 and
S1P4 being strongly expressed in T cells [27]. S1P1 is particularly
associated with lymphocyte migration. In some clinical reports of
FTY720, symptomatic bradycardia was noted as an adverse event
[28], and this is related to agonistic activity of S1P3 [29]. W-061
was found to have a lower affinity for S1P1, but to have a much
lower affinity for and S1P3 than FTY720 phosphate (Table 1).
Thus, it could be considered that W-061 had a higher selectivity
for S1P1 than FTY720 phosphate. In addition, W-061 had little
agonistic activity on S1P3 (Table 2). Taken together, these
properties may be helpful not only for adjusting lymphocyte
trafficking with less adverse events such as symptomatic brady-
cardia.
The recent advances in our knowledge of the immunopatho-
logic basis of IBD have been approaching the elucidation of the
inflammatory cytokines driving the two main components of IBD,
CD and UC. CD patients, but not UC patients, exhibit elevated
amounts of IFN-c in the inflamed LP, suggesting the presence of a
Th1-mediated inflammatory process. Recently, a novel helper T
cell, Th17, was identified, and was reported to be a proin-
Table 1. Binding affinity of W-061 on S1P receptors.
hS1P1 hS1P2 hS1P3 hS1P4 hS1P5
S1P 0.131 0.439 0.0782 7.60 0.372
FTY720-P 0.160 4090 3.74 2.16 1.09
W-061 4.11 .43800 1710 65.4 10.1
Data were shown as Ki value. FTY720-P; FTY720-phosphate.
doi:10.1371/journal.pone.0023933.t001
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case of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis,
it was also shown to be driven by a cytokine including IL-12p40
and to be reversed by anti-IL-12p40 mAb [30]. Furthermore, it
was found that a novel cytokine, IL-23, shared the common p40
chain with IL-12 [31]. It is generally recognized that Th17 cells
are induced by IL-23 together with TGFb, while Th1 cells are
induced by IL-12 or IL-23 without TGFb [6]. Therefore, anti-IL-
12p40 mAb inhibits Th17 as well as Th1.
Although the role of Th1 is reported to be an indispensable
subset [32], the role of Th17 remains controversial in DSS-
induced colitis or the CD4
+ CD45RB
high lymphocyte transfer
model. In the case of DSS-induced colitis, inflammation is
improved in IL-17-deficient mice [12], but is aggravated by
neutralization of IL-17 due to anti-IL-17 mAb [13]. In the
adoptive transfer model, transfer of RORc-null T cells do not
induce colitis [14]; however, lymphocytes from IL-17A-deficient
mice induced severe colitis [15]. Thus, the type of colitis model or
the time of inflammation may influence whether Th1 or Th17
cells contribute the pathogenesis of colitis.
In the previous reports, however, we did not evaluate the effects
of S1P receptor agonists on the new T cell subsets, such as Th17
and Treg. In order to investigate the effect of W-061 on these T
cells, we utilized a DSS-induced mice colitis model which does not
exhibit any immune disorder, in contrast to IL-10 deficient mice.
Treg cells cannot be evaluated in IL-10-deficient mice because IL-
10 is necessary for the effector function of the regulatory T cell
population [32]. We showed that the number of Th17 cells in LP
was markedly higher after the initiation of colitis, and then
decreased significantly, which appears to be due to the induction
of Treg cells. After downregulation of Th17 cells, it is likely that
IFN-c-producing Th1 cells prolong the inflammation in LP.
In contrast, when W-061 was administered, the number of Th1
and Th17 cells was markedly decreased in the acute phase of
inflammation. Interestingly, W-061 did not influence the migra-
tion of Treg cells. These data suggest that W-061 promotes the
migration of Th17 and Th1 cells, but not Treg cells into secondary
lymphoid tissues. It is generally known that S1P receptor agonists
do not affect migration of memory T and B cells into secondary
lymphoid tissues, resulting in the maintenance of the anti-
opportunistic infections or anti-tumor effects [24-26]. The
chemokine receptor CCR7 is reported to be a major homing
receptor in T cells [33]. Although CCR7 is expressed in Treg cells,
as well as other T cell subsets, its effects differ between naı ¨ve-like
Treg and effector/memory-like Treg [34]. Namely, naı ¨ve like
Treg can enter themelves into lymph node via CCR7 to control
the priming phase of immune responses. On the other hand,
CCR7 on effector/memory Treg is associated to emigrate
Figure 1. DSS-induced colitis was ameliorated by W-061 treatment. (A) Change in body weight of W-061-treated and control mice with the
DSS-induced colitis (n=6 mice for each group, *p,0.05). (B) Pathological evaluation of the DSS-induced colitis on day 10. (C) Histological score of the
DSS-induced colitis on day 10. Data represent absolute values (means 6 SD, n=6 mice for each group, *p,0.05).
doi:10.1371/journal.pone.0023933.g001
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W-061 is likely to have some selectivity. Considering that
accumulation of effector/memory-like Treg at inflamed sites was
induced by CCR7 deficiency [34], W-061 may affect CCR7
expression. Further study is thus needed to clarify whether
migration of Treg via S1P1 receptor is different from that of
other T cell subsets.
In summary, we herein demonstrate that a novel S1P receptor
agonist W-061 is effective in the treatment of acute colitis
induced by DSS. This effect is attributed to the suppression of
increases in Th17 and Th1 in LP by the sequestration of these
cells into the secondary lymphoid tissues. Thus, Th17 and Th1
in LP are a key subset in the pathogenesis of DSS-induced colitis.
S1P receptor agonists, including W-061, may therefore represent




CHO-K1 cells stably expressing human S1P1 (hS1P1), human
S1P2 (hS1P2), human S1P3 (hS1P3), human S1P4 (hS1P4)o r
human S1P5 (hS1P5) were cultured in Ham’s F12 medium
supplemented with 10% bovine serum (Sigma-Aldrich, St Louis,
MO) and 0.25 mg/mL G418 sulfate (Invitrogen, Carlsbad, CA) in
5% CO2/95% air at 37uC.
Membrane binding assay
Membranes were prepared from CHO-K1 cells stably expressing
human S1P receptors based on the methods of Mandala et al. [35].
Briefly, cells were washed in PBS, suspended in 10 mM Tris-HCl
(pH 7.5), 5 mM EDTA, and 1x Complete protease inhibitor
cocktail (Roche Diagnostics, Mannheim, Germany), and were
disrupted on ice using a polytron homogenizer. Following
centrifugation at 80,000 6 g for 40 min at 4uC, the pellet was
suspended in 10 mM Tris-HCl (pH 7.5), 10% glycerol, and 1x
Complete protease inhibitor cocktail and stored at 280uC. [
33P]-
S1P (American Radiolabeled Chemicals, St. Louis, MO) were used
asradio-labeled ligands.Test compoundsinassaybuffer1 (forS1P1,
S1P2, S1P3, and S1P5; 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2,
0.5% fatty acid-free BSA, and 1x Complete protease inhibitor
cocktail) or assay buffer 2 (for S1P4 50 mM Tris-HCl, pH 7.5,
100 mM NaCl, 15 mM NaF, 0.5% fatty acid-free BSA, and 1x
Complete protease inhibitor cocktail) were added to a 96-well plate.
Radio-labeled ligands and membranes were added to give a final
volume of 200 mL. Binding was performed for 60 min at room
temperature and was terminated by collecting the membranes onto
unifilter GF/B plates (Perkin Elmer, Boston, MA) with a
UniFilter96 Harvester (Perkin Elmer). After drying the filter plates
for 30 min, filter-bound radionuclides were measured on a
TopCount NXT microplate scintillation counter (Perkin Elmer).
Specific binding was calculated by subtracting the radioactivity that
remained in the presence of a 1000-fold excess of unlabeled S1P.
Figure 2. Change of the numbers of CD4
+ T cells in (A) SP, (B) MLN, (C) PP and (D) LP. Data represent absolute values (means 6 SD, n=4
per group on days 3 and 6, n=6 per group on day 10, * p,0.05).
doi:10.1371/journal.pone.0023933.g002
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CHO-K1 cells stably expressing hS1P1 or hS1P3 were plated at
2610
4 cells/well in 96-well plate and incubated for 2 days at
37uCi n5 %C O 2/95% air. Cells were loaded with Ham’s F12
medium containing 5 mM Fura2-AM and 20 mM HEPES
(pH 7.4) at 37uC for 1 h. After loading, cells were washed with
Hanks solution containing 20 mM HEPES (pH 7.4), and
stimulated with test compounds. Fluorescence intensity was
measured by the ratio of emission fluorescence at 500 nm by
excitation at 340 and 380 nm using a Fluorescence Drug
Screening System (FDSS-6000, Hamamatsu Photonics K.K.,
Shizuoka, Japan).
Mice
Six- to 7-week-old male Balb/c mice were purchased from
Charles River Japan, Inc. (Kanagawa, Japan). Before use, mice
were maintained in a specific pathogen-free animal facility Fat the
Institute of Experimental Animal Sciences, Osaka University
Graduate School of Medicine, and were kept in a room
maintained at 25uC with a 12 h light/dark cycle and free ac-
cess to food and water. All experiments were performed in
accordance with the Guidelines for Animal Experiments of Osaka
University. The protocol was approved by the Committee on the
Ethics of Animal Experiments of Osaka University (approval ID:
J003549-009). All surgery was performed under sevoflurane
anesthesia, and all efforts were made to minimize suffering.
Drug Treatment
Colitis was induced by 2.5% w/v DSS (MW: 5000, Wako,
Osaka, Japan) in drinking water for 5 days. W-061 (Ono
Pharmaceutical, Osaka, Japan) was dissolved in 0.5% w/v
methylcellulose solution. The drug was administered orally at a
dose of 3 mg/kg/day. After induction of colitis, daily clinical
assessment of colitis was performed by measuring body weight and
food intake, and observing fecal properties. Mice were sacrificed
on day 3, 6 or 10.
Isolation of lymphocytes
Lymphocytes were isolated from spleen (SP), mesenteric lymph
nodes (MLN), Peyer’s patches (PP) and lamina propria (LP) using
a modification of the method reported by Atarashi et al. [36].
Briefly, single-cell suspensions were obtained by gently pressing
the SP and MLN, filtered through 70-mm nylon meshes and
suspended in HBSS (Wako) supplemented with 2% fetal bovine
serum (FBS). Cells from lymphocytes were treated with RBC lysis
buffer (eBioscience, San Diego, CA) before suspension. To
prepare single-cell suspensions from PP, tissues were treated with
RPMI 1640 (Sigma-Aldrich) containing 2% FBS and 1 mg/mL
collagenase type II (Invitrogen) for 20 min at 37uC. For isolation
from LP lymphocytes, intestines were opened longitudinally,
washed with ice-cold PBS to remove fecal content, and were
shaken in HBSS supplemented with 2% FBS and 5 mM EDTA
for 20 min at 37uC. Intestines were then cut into small pieces and
Figure 3. Change of the numbers of Th17 cells in (A) SP, (B) MLN, (C) PP and (D) LP. Data represent absolute values (means 6 SD, n=4 per
group on days 3 and 6, n=6 per group on day 10, * p,0.05).
doi:10.1371/journal.pone.0023933.g003
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collagenase type II for 25 min at 37uC. Digested tissues were
resuspended with 8 mL of 40% Percoll (GE Healthcare,
Waukesha, WI) and overlaid on 4 mL of 75% Percoll. Gradient
separation was performed by centrifugation at 760 6 gf o r
20 min at 37uC. Lymphocytes were collected at the interface of
the Percoll gradient, washed and suspended in RPMI 1640
containing 2% FBS.
Flow Cytometric Analysis
Anti-CD4 monoclonal antibody (mAb) (RM4-5), anti-IL-17A
mAb (TC11-18H10.1), anti-IFN-c mAb (XMG1.2) and anti-
CD25 mAb (PC61) were purchased from Becton Dickinson, and
anti-Foxp3 mAb (FJK-16s) was purchased from eBioscience.
Intracellular expression of IL-17, IFN-c or Foxp3 in CD4
+ T
cells were analyzed using a Cytofix/Cytoperm Kit (Becton
Dickinson) according to the manufacturer’s instructions. Briefly,
lymphocytes from SP, MLN, PP or LP were incubated with
50 ng/mL phorbol myristate acetate (Sigma), 5 mM calcium
ionophore (Sigma) and Golgistop (Becton Dickinson) at 37uC for
4h .
For Th17 and Th1 determination, surface staining for
lymphocytes were performed with a cocktail of fluorescently
labeled anti-CD4 mAb for 30 min at 4uC. Subsequently, cells
were permeabilized with Cytofix/Cytoperm for 20 min at 4uC,
and intracellular cytokine staining was performed with fluores-
cently labeled anti-cytokine antibodies for 30 min at 4uC.
Similarly, for Treg determination, lymphocytes were stained with
a cocktail of fluorescently labeled anti-CD4 mAb and anti-
CD25 mAb. After Cytofix/Cytoperm treatment, cells were
stained with fluorescently labeled anti-Foxp3 mAb. Stained
lymphocytes were analyzed on a FACSCalibur Flow Cytometer
(Becton Dickinson) using Cell Quest software. Among lymphocytes,
CD4
+ IL-17
+ cells were considered to be Th17. Similarly, CD4
+
IFN-c




+ lymphocytes were considered to be Treg.
Histological Analysis of Colon
Histological analysis was performed on colon divided into
three areas; proximal, medial and distal. Tissue was fixed in 4%
paraformaldehyde in PBS and embedded in paraffin. Sections
(2 mm) were prepared and stained with hematoxylin and eosin.
Histopathologic changes in the colonic mucosa were semi-
quantified according to a modified scoring system
18: (a) cellular
infiltration in the lamina propria (scored from 0 to 3); (b) mucin
depletion (scored from 0 to 2); (c) crypt abcesses (scored from 0 to
2); (d) epithelial erosion (scored from 0 to 2); (e) hyperemia
(scored from 0 to 3); and (f) thickness of mucosa (scored from 1
to 3).
Statistical analysis
All data are expressed as means 6 SD. Data were analyzed by
two-tailed Student’s t test. Values of p,0.05 were considered to be
significant.
Figure 4. Change of the numbers of Th1 cells in (A) SP, (B) MLN, (C) PP and (D) LP. Data represent absolute values (means 6 SD, n=4 per
group on days 3 and 6, n=6 per group on day 10, * p,0.05).
doi:10.1371/journal.pone.0023933.g004
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Figure S1 The change in body weight was not affected
with daily administration of W-061 (3 mg/kg). Data
represent absolute values (means 6 SD, n=6).
(TIF)
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